| Literature DB >> 32645594 |
Abdelrahman Abdelaal1, Walid El Ansari2, Abdelrahman Abusabeib3, Hanan Farghaly4, Abdelhakem A M Tabeb5.
Abstract
BACKGROUND: Papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) are the first and second most common thyroid cancers comprising about 85% and 10% of all thyroid cancers. Simultaneous occurrence of medullary and papillary thyroid cancer has been reported with various presentations, but simultaneous occurrence of FTC in addition to PTC as differentiated cancers, is an unusual event that is rarely reported. PRESENTATION OF CASES: We report our experience of six rare cases of synchronous coexistence of FTC and PTC with unique features. Case 1 is 31 old Egyptian female. Case 2 is a 61 year old Sudanese male. Case 3 is a 59 year old Sudanese male. Case 4 is a 56 years old Indian female. Case 5 is a 35 years old Filipina female. Case 6 is a 52 years old Qatari female. The six cases are special in their co-occurrence of two thyroid carcinoma, consisting of histologic features of follicular thyroid carcinomas, and classical papillary thyroid carcinoma, possibly the first case series of simultaneous occurrence of these two types of thyroid cancer in the Middle East and North Africa Region.Entities:
Keywords: Differentiated; Follicular thyroid carcinoma; Papillary thyroid carcinoma
Year: 2020 PMID: 32645594 PMCID: PMC7341056 DOI: 10.1016/j.ijscr.2020.06.070
Source DB: PubMed Journal: Int J Surg Case Rep ISSN: 2210-2612
Fig. 1Papillary thyroid carcinoma with characteristic nuclear features (nuclear crowding, overlapping, clearing, membrane irregularities and inclusions).
Fig. 2Thyroid follicular carcinoma widely invading the thyroid capsule.
Summary of characteristics of six patients with concurrent follicular thyroid carcinoma and papillary thyroid carcinoma.
| Case | Age | Sex | Country | Path | Side | Focus | Size (cm) | AJCC stage | Margins | Invasion | EE | Rx | Follow up | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L | PN | AI | Scan | Lab | ||||||||||||
| 1 | 31 | F | Egypt | FTC | L | U | 5 × 4 | pT3 N0 | UI | N | N | N | N | L hemi T; completion R hemi T; 2 fractionated doses RI (30 mci) | No evidence of RI avid local/distant path; No residual/recurrence in TY | Very low TG (<0.1 ng/mL) and TGA (<0.9 IU/mL) |
| PTC | L | U | 1.3 | pT1b N0 | N | N | N | N | ||||||||
| 2 | 61 | M | Sudan | FTC | R | U | 6 × 3 × 2.7 | pT3a Nx | UI | N | N | Y | N | R hemi T; completion L hemi T; high dose RI (100 mci) | No evidence of residual TY tissue/metastatic tumor/focal lesion in TY bed | Very low TG (<0.2 ng/mL) and TGA (<0.9 IU/mL) |
| PTC | R | U | 0.3 | pT1a Nx | UI | — | — | — | — | |||||||
| 3 | 59 | M | Sudan | FTC | L | U | 5 | pT3a Nx | I | Y | N | N | N | Completion L T; RI ablation 100 mci | Residual TY tissue; received another 30 mci RAI. US Neck follow up showed no residual TY tissue | TG 3.6 ng/mL, TGA 1.2 IU/mL |
| PTC | L | U | 1.5 | pT1bp Nx | I | N | N | N | N | |||||||
| 4 | 56 | F | India | FTC | L | U | 4.5 × 3.5 × 2.5 | pT3a Nx | I | Y | N | N | N | Total T, then post T high dose RI ablation | Patient travelled out of the country, lost to follow up | |
| PTC | L | M | 0.6 MD | pT1a Nx | UI | — | — | — | — | |||||||
| R | M | 1 × 0.8 × 0.7 | pT1a Nx | UI | N | N | N | N | ||||||||
| R | M | 0.5 MD | pT1a Nx | UI | — | — | — | — | ||||||||
| 5 | 35 | F | Philippines | FTC | R | U | 1.3 | pT1b N0 | UI | N | N | N | N | Total T | Patient travelled out of the country, lost to follow up | |
| PTC | R | M | 0.8 | pT1a N0 | UI | N | N | N | N | |||||||
| 6 | 52 | F | Qatari | FTC | R | U | 2.7 × 1.5 × 1.5 | pT2 Nx | UI | N | N | N | N | Total T, then post T low dose RI ablation | Residual TY tissue; US Neck follow up showed residual TY tissue | TG 0.2 ng/mL, TGA < 0.9 IU/mL |
| PTC | R | U | 0.8 × 0.6 × 0.4 | pT1a Nx | UI | N | N | N | N | |||||||
Micro papillary carcinoma; AI Angio-invasion; AJCC American Joint Commission pTNM [9]; EE Extrathyroid extension; F female; FTC; follicular thyroid carcinoma; I involved; L left; L lymphatic; Lab laboratory; M male; M multifocal; MD maximum dimension; N no; Path Pathology; PN Peri-neural; PTC papillary thyroid carcinoma; R right; RI radioactive iodine; Rx treatment; Rx treatment; T thyroidectomy; TG thyroglobulin; TGA thyroglobulin antibodies; TY thyroid; U unifocus; UI uninvolved; Y yes.